[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"obsessive-compulsive-disorder-ocd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:obsessive-compulsive-disorder-ocd":26},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,38,0,25,[9,45,57,88,112,139,166,190,209,239,261,284,314,355,376,414,435,461,483,530,551,583,609,695,717],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100054278","role-of-theta-frequency-oscillations-in-proactive-and-reactive-control-processes-in-youth-with-attention-deficit-hyperactivity-disorder-adhd-and-obsessive-compulsive-disorder-ocd-100054278",false,"NCT07566468","Role of Theta Frequency Oscillations in Proactive and Reactive Control Processes in Youth With Attention Deficit Hyperactivity Disorder (ADHD) and Obsessive Compulsive Disorder (OCD)","* INCLUSION CRITERIA\n\n  1. Ability to provide informed assent and parent consent\n  2. Age: 10-17 years\n  3. ADHD Group: Diagnosis of ADHD based on DSM-5 criteria\n\n     OCD Group: Diagnosis of OCD based on DSM-5 criteria\n\n     HV Group: No Neurological or Psychiatric diagnosis based on DSM-5 criteria\n  4. Wechsler Abbreviated Scale of Intelligence, Second Edition (WASI-II). WASI-II will be used as a measure of intellectual function. Children will be included when FSIQ \\> 70.\n  5. Normal or corrected to normal vision\n\nEXCLUSION CRITERIA\n\nParticipants will be screened to exclude participants in whom MRI or EEG might result in increased risk of side effects or complications or whose data would not be scientifically valid.\n\n1. Non-English Speakers\n2. Pregnancy\n3. Any implant, prosthesis or alteration of the body that, in the opinion of the investigator, would be unsafe with MRI or EEG or that would produce an artifact that would compromise the integrity of data;\n4. Active or History of psychosis, bipolar I disorder, Level 2 or 3 autism spectrum disorder, active severe substance use disorders (within the last month), have active suicidal intent or plan as detected on screening instruments;\n5. Individuals currently taking Stimulant medications who are unwilling or unable to not take the medication during study visit days.\n6. Past or present medical or neurological condition, disease, disorder, genetic finding, or injury that, in the opinion of the Investigator, may significantly increase the potential risks of study participation, reduce or compromise a subject s ability to fully comply with all study requirements for the duration of the study or may compromise the integrity of the data.\n7. For the HV group, any impairing current psychiatric diagnosis.","ALL","10 Years","17 Years",{"count":20,"type":21},110,"ESTIMATED","OBSERVATIONAL","Background:\n\nAttention deficit hyperactivity disorder (ADHD) is common in children. It can cause problems with attention and the ability to control actions and impulses. Obsessive compulsive disorder (OCD) is less common in children but not rare. It involves ongoing thoughts, urges, impulses, and repeated behaviors. Researchers want to study differences in brain activity between healthy children, those with ADHD, and those with OCD.\n\nObjective:\n\nTo learn more about how the brain controls thinking and behavior.\n\nEligibility:\n\nPeople aged 12 to 17 years with ADHD, OCD, or neither.\n\nDesign:\n\nParticipants will have 3 to 10 clinic visits in up to 1 year. Each visit will last 2 to 3 hours.\n\nThree visits are required:\n\nBehavioral. Participants will complete a computer task. Their mood, memory, attention, and thinking skills will be tested.\n\nEEG. Participants will undergo electroencephalography (EEG) to measure signals in their brain. Small electrodes will be placed on the scalp. A cap will be stretched over the head. Signals will be recorded while participants rest or do tasks on a computer.\n\nMRI. Participants will have a magnetic resonance imaging scan (MRI). They will lie on a table that rolls into a tube. The MRI will take pictures of their brain while they do tasks on a computer.\n\nSeven more visits are optional. These include 2 more EEG visits and 2 more MRI visits.\n\nThree will be magnetoencephalography (MEG) visits: MEG measures small magnetic field changes in the brain. A helmet with sensors will be placed on the head. Brain changes will be recorded while participants rest or do tasks on a computer.",[25,26,27],"ADHD","Obsessive Compulsive Disorder (OCD)","Healthy Volunteer",[29,30,31],"EEG","MRI","fMRI","NOT_YET_RECRUITING","2026-07-10",{"date":35,"type":36},"2026-07-13","ACTUAL",{"date":38,"type":21},"2026-07-16",{"date":40,"type":21},"2029-05-31",{"name":42,"class":43},"National Institute of Mental Health (NIMH)","NIH",1,{"id":46,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":47,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":48,"keywords":49,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":56,"locationsCount":44},"100636498",{"count":20,"type":21},[25,26,27],[29,30,31],"2026-07-01",{"date":52,"type":36},"2026-07-02",{"date":54,"type":21},"2026-07-07",{"date":40,"type":21},{"name":42,"class":43},{"id":58,"slug":59,"hasResults":12,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":4,"eligibilityCriteria":63,"healthyVolunteers":12,"sex":16,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":4,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":44},"100600931","aerobic-exercise-and-obsessive-compulsive-disorder-symptoms-100600931","NCT07103902","Aerobic Exercise and Obsessive-Compulsive Disorder Symptoms","Effects of Aerobic Exercise on Obsessive-Compulsive Disorder Symptoms and Cognitive Flexibility","Inclusion Criteria:\n\n* Adults, age 18 to 64 years\n* Meet diagnostic criteria for OCD (per the DIAMOND)\n* Stable psychiatric or medication treatment (if ≥4-weeks), or if no active treatment. Psychotropic medications will be reviewed with the study psychiatrist on a case by case basis.\n\nExclusion Criteria:\n\n* Active or unmanaged psychotic disorders, pervasive developmental disorders, bipolar disorder, current substance use disorder (moderate-to-severe), or high risk for suicide (defined as attempt, plan, or intent within past 3 months)\n* Documented motor impairments and medical condition(s) that prohibit physical exercise\n* Those who are pregnant or trying to become pregnant","18 Years","64 Years",{"count":67,"type":21},50,"INTERVENTIONAL",[70],"NA","The purpose of this study is to examine the acute effects of exercise on cognitive flexibility and symptom reactivity. The main questions it aims to answer are:\n\nDoes moderate intensity physical activity reduce subjective distress, compulsive urges, and intrusions- and increase cognitive flexibility- in adults with obsessive-compulsive disorder compared to low-intensity physical activity?\n\nResearchers will compare low- to moderate-intensity exercise to see if moderate physical activity increases cognitive flexibility and reduces symptom reactivity in adults with obsessive-compulsive disorder (OCD).\n\nParticipants will:\n\nComplete self-report surveys, psychiatric interviews, and cognitive tasks.\n\nBe assigned to either a low- or moderate-intensity exercise condition and complete physical activity.\n\nRepeat cognitive and symptom measures following the exercise intervention.",[73],"Obsessive-Compulsive Disorder (OCD)",[75,76,77],"Anxiety Disorders","Mental Disorders","Obsessive-Compulsive Disorder","RECRUITING","2026-06-30",{"date":52,"type":36},{"date":82,"type":36},"2026-02-16",{"date":84,"type":21},"2026-09-01",{"name":86,"class":87},"Yale University","OTHER",{"id":89,"slug":90,"hasResults":12,"nctId":91,"briefTitle":92,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":12,"sex":16,"minAge":64,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":68,"phases":96,"briefSummary":97,"conditions":98,"keywords":99,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":44},"100451563","connectomic-deep-brain-stimulation-for-obsessive-compulsive-disorder-100451563","NCT05160129","Connectomic Deep Brain Stimulation for Obsessive Compulsive Disorder","All participants will receive ALIC DBS for OCD. DBS received a Humanitarian Device Exemption (HDE) in 2009 with an indication for bilateral stimulation of the ALIC as an adjunctive treatment to medications and as an alternative to anterior capsulotomy for treatment of chronic, severe, treatment-refractory OCD in adult patients who have failed at least three SSRIs. Additionally, more stringent criteria have been selected for defining treatment-resistance in this protocol, as indicated below.\n\nINCLUSION CRITERIA:\n\n* 18 years of age or older\n* Primary psychiatric diagnosis of Obsessive-Compulsive Disorder (OCD, per DSM-5 criteria)\n* Meets FDA Humanitarian Device Exemption (HDE) criteria for indication\n* Has elected to receive clinically indicated DBS for OCD with a directional system outside of this research study, as determined by treating clinician(s) and per current clinical practice\n* Minimum of a five-year history of treatment-refractory OCD with substantial functional impairment\n* Failure of an adequate trial of at least three of the following SSRIs: Fluoxetine, Fluvoxamine, Citalopram, Escitalopram, Sertraline, Paroxetine\n* Failure of an adequate trial of clomipramine\n* Failure of an adequate trial of one or more of the aforementioned antidepressants in combination with at least one of the following augmentation agents: Haloperidol, Risperidone, Olanzapine, Quetiapine, Ziprasidone, Aripiprazole\n* Failure of an adequate trial of Cognitive Behavioral Therapy (CBT), defined as 25 hours of documented exposure and response prevention (ERP) by an expert therapist\n* Minimum score of 25 on the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) at preoperative baseline\n* Ability to undergo preoperative MRI\n* English proficiency\n* Capacity to provide written informed consent\n* Willing and able to comply with all device operation and study-related procedures\n\nEXCLUSION CRITERIA:\n\n* Ineligible or unwilling to receive ALIC DBS for OCD\n* Contraindications for general anesthesia, neurosurgery, or an MRI scan\n* Neurological disorder or other significant brain pathology, such as moderate \u002F marked cerebral atrophy, stroke, tumor, epilepsy, or previous neurosurgical procedures (excluding cingulotomy, which may be permitted if not contraindicated in the opinion of implanting neurosurgeon)\n* Unstable medical illness, chronic immunosuppression, and\u002For considerably reduced life-expectancy\n* Conditions requiring anticoagulant therapy which cannot be discontinued for the perioperative period, as required\n* Conditions requiring certain regular MRI scans or diathermy\n* Currently implanted with a cardiac pacemaker \u002F defibrillator or other implanted electrical device which may interfere with DBS stimulator or the function of which may be impacted by its implantation, in the opinion of evaluating neurosurgeon\n* Other primary Axis I disorder or history of psychosis, such as schizophrenia, psychosis in the context of depressive or manic episode.\n* Current or past history within the 6 months prior to DBS implantation of substance abuse or dependence (excluding nicotine and caffeine)\n* Active suicidal ideation with intent, suicide attempt within the last six months, more than three suicide attempts within the last two years, or serious suicide risk as determined by the study psychiatrists\n* Axis II disorders which, in the opinion of the study psychiatrist, may increases the risk of DBS to participants or cause study non-compliance\n* Patients who lack the capacity to for proper device usage and maintenance, in the opinion of the research team\n* Women who are pregnant",{"count":95,"type":21},22,[70],"Deep brain stimulation (DBS) is an effective treatment for people suffering from severe obsessive-compulsive disorder (OCD) whose symptoms have failed to improve after years and multiple methods of intervention. An effective DBS target for OCD is the anterior limb of the internal capsule (ALIC) brain region. On average 60% of all OCD patients have a clinically significant response to ALIC DBS. However, ALIC DBS may become even more effective with the ability to predict which specific ALIC connections in the brain need to be stimulated for each individual OCD patient. This study therefore investigates personalized stimulation to the ALIC that allows for precise modulation of brain circuits associated with individual OCD symptoms. The study aims to specify the ideal anatomical target for ALIC DBS for maximum therapeutic benefit in each patient.",[26],[100,26,101,102],"Deep Brain Stimulation (DBS)","Anterior Limb of Internal Capsule (ALIC)","Circuit Modulation","2026-06-22",{"date":105,"type":36},"2026-06-25",{"date":107,"type":36},"2021-08-13",{"date":109,"type":21},"2027-02-28",{"name":111,"class":87},"Icahn School of Medicine at Mount Sinai",{"id":113,"slug":114,"hasResults":12,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":120,"sex":16,"minAge":64,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":134,"leadSponsor":136,"locationsCount":138},"100643022","non-coding-rnas-gene-expression-in-psychiatric-disorders-100643022","NCT07649993","Non-Coding RNAs Gene Expression in Psychiatric Disorders","Gene Expression Analysis of Non-coding RNAs in Psychiatric Disorders","PsiRNA26","Inclusion Criteria (patients):\n\n* Age between 18 and 55 years;\n* Male sex or female sex in the mid-luteal phase of the menstrual cycle;\n* Clinical presentation consistent with diagnostic criteria for:\n* Bipolar Disorder type I or II,\n* Panic Disorder,\n* Major Depressive Disorder,\n* Obsessive-Compulsive Disorder,\n* Schizophrenia;\n* First diagnosis and drug-naive status, or absence of psychopharmacological treatment for at least 6 months prior to enrollment.\n\nInclusion Criteria (Healthy Control):\n\n* Age between 18 and 55 years;\n* Male sex or female sex in the mid-luteal phase of the menstrual cycle;\n* No treatment with psychotropic medications;\n* Absence of clinical elements supporting a diagnosis of Bipolar Disorder, Panic Disorder, Major Depressive Disorder, Obsessive-Compulsive Disorder, Schizophrenia;\n* Absence of clinical or laboratory evidence of infectious or internal medicine diseases;\n* Absence of autoimmune diseases;\n* HAM-D score \\\u003C 8;\n* MRS score \\\u003C 11;\n* Y-BOCS score \\\u003C 7;\n* BPRS score = 18;\n* No significant stressful life events during the previous 6 months.\n\nExclusion Criteria (patients):\n\n* Current immunosuppressive, antibiotic, or hormone replacement therapy;\n* Relevant medical comorbidities, including autoimmune or internal medicine disorders;\n* Active infectious diseases or infections resolved less than 3 weeks before enrollment;\n* Relevant psychiatric comorbidities;\n* Current psychopharmacological treatment or discontinuation of psychopharmacological therapy less than 6 months before enrollment.",true,"55 Years",{"count":123,"type":21},384,"This study aims to investigate whether specific non-coding RNAs, molecules involved in the regulation of gene expression, are altered in individuals with psychiatric disorders such as schizophrenia, bipolar disorder, major depressive disorder, panic disorder, and obsessive-compulsive disorder. Researchers will compare the expression levels of these molecules in patients who are drug-naïve or have been free from psychiatric treatment for at least six months with those observed in healthy volunteers.\n\nThe study will also evaluate whether the expression of these non-coding RNAs changes after approximately five months of standard psychiatric treatment. Blood samples collected during routine clinical care will be used to measure the expression levels of selected non-coding RNAs using reverse transcription quantitative polymerase chain reaction (RT-qPCR), a laboratory technique used to assess gene expression.\n\nThis is an observational study and does not assign specific treatments. All therapies will be prescribed according to standard clinical practice.\n\nThe main objective is to determine whether alterations in non-coding RNA expression may serve as biological markers of psychiatric disorders and whether these markers may help monitor treatment-related changes over time. The findings may contribute to a better understanding of the biological mechanisms underlying major psychiatric disorders and support the future development of more accurate diagnostic and therapeutic approaches.",[126,127,128,26,129],"Schizophrenia Disorders","Major Depression","Bipolar Affective Disorders","Anxiety Disorder (Panic Disorder or GAD)","2026-06-18",{"date":132,"type":36},"2026-06-23",{"date":84,"type":21},{"date":135,"type":21},"2028-09-01",{"name":137,"class":87},"Carmen Concerto",5,{"id":140,"slug":141,"hasResults":12,"nctId":142,"briefTitle":143,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":12,"sex":16,"minAge":64,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":148,"conditions":149,"keywords":151,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":165},"100561921","neurophysiological-investigation-of-the-approach-avoidance-axis-in-ocd-applications-to-neuromodulation-100561921","NCT06596447","Neurophysiological Investigation of the Approach-avoidance Axis in OCD: Applications to Neuromodulation","Inclusion Criteria:\n\n1. Principal diagnosis of OCD per DSM-5;\n2. Adult between ages 18 and 64;\n3. At least a five-year history of treatment-refractory OCD that causes substantial subjective distress and impairment in functioning;\n4. Minimum score of 28 on the Y-BOCS;\n5. Failed an adequate trial of at least three SSRIs;\n6. Failed an adequate trial of clomipramine;\n7. Failed augmentation of one or more of the aforementioned drugs with at least one anti-psychotic medication;\n8. Failed an adequate trial of CBT for OCD, defined as 25 hours of documented exposure and response prevention (ERP) by an expert therapist;\n9. Stable psychotropic medical regimen for the month preceding surgery;\n10. Principal diagnosis of OCD who are approved by our multi-disciplinary team to undergo DBS surgery within two months of enrollment;\n11. Ability to provide fully informed, written consent;\n12. Availability of a family member or significant other who is willing to accompany patients to study visits if necessary.\n\nExclusion Criteria:\n\n1. Lifetime diagnosis of psychotic disorder such as schizophrenia;\n2. Alcohol or substance abuse\u002Fdependence within 6 months, excluding nicotine;\n3. Concern for high risk of suicidal behavior or impulsivity;\n4. Patient is \\[regnant or plans to become pregnant in the next 24 months;\n5. Need for diathermy;\n6. Existence of any neurological or medical condition\u002Fdisorder that makes the individual, in the opinion of the study team, a poor candidate to participate in the intended study procedures\n7. Comorbid psychiatric disorder that, in the opinion of the study team, may interfere with the candidate's ability to participate in study activities;\n8. Primary diagnosis of a Hoarding Disorder.","70 Years",{"count":147,"type":21},10,"We will recruit 10 patients with OCD meeting established criteria for surgical evaluation. Following informed consent and baseline evaluations, each will be implanted with permanent DBS SenSight leads and the Medtronic Percept RC IPG, which has on-device neural recording capability and rechargeability.\n\nWe will collect a broad array of neurobehavioral data across two environments with complementary advantages: the clinic and the home. The first 2 Aims test our mechanistic hypothesis by studying the pattern of VS neural activity in the controlled environment of the lab\u002Fclinic during two complementary paradigms: one based on a psychophysical behavioral task, the other based on ERP, a therapeutic behavioral intervention. The third aim tests this hypothesis in an ambulatory, naturalistic setting with chronic neural on-device recordings paired with time resolved behavioral measures. We will investigate a possible common neural basis underlying approach and avoidance across these 3 paradigms.\n\nSubjects will participate in research at 7 critical timepoints during routine clinic visits (Fig. 4): before implant, 1 day before DBS activation, immediately after DBS activation, 2 weeks, 3 months, 6 months, and 12 months after DBS initiation. At these timepoints, patients will complete clinical assessments, perform the Probabilistic Approach Avoidance Task (PAAT), and conduct exposure trials under the guidance of a psychologist. The clinic offers the most controlled environment and provides opportunities for collecting high temporal resolution behavior synchronized to local field potential (LFP) recordings. These data will allow us to identify the degree of overlap in the time-resolved neural activity driving individual decisions to approach potential rewards or avoid potential aversive stimuli (Aim 1), and resist performing compulsions in order to achieve relief after OCD symptoms are triggered (Aim 2).\n\nAt home, our goal is to investigate patient trajectories along the approach-avoidance axis as OCD symptoms improve (Aim 3). We will leverage passive, on device recordings that occur in the background of everyday life activities and synchronize these neural recordings with data collected via wearables, ecological assessments, and video diaries. Capturing neural and behavioral data in the home environment is essential for understanding the neural and behavioral changes that occur over longer timescales than individual clinical visits. The neurobehavioral biomarkers generated by this dataset will provide trackable readouts of clinical status that could inform therapeutic decision-making and enable data driven intervention.",[26,150],"Neuromodulation",[152,153,154,155],"Obsessive Compulsive Disorder","OCD","Deep Brain Stimulation","DBS","2026-06-16",{"date":158,"type":36},"2026-06-17",{"date":160,"type":21},"2026-08-01",{"date":162,"type":21},"2030-07-31",{"name":164,"class":87},"Baylor College of Medicine",2,{"id":167,"slug":168,"hasResults":12,"nctId":169,"briefTitle":170,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":12,"sex":16,"minAge":64,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":68,"phases":174,"briefSummary":175,"conditions":176,"keywords":177,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":44},"100642729","bergen-four-day-treatment-b4dt-for-obsessive-compulsive-disorder-100642729","NCT07644130","Bergen Four-Day Treatment (B4DT) for Obsessive-Compulsive Disorder","Inclusion Criteria:\n\n* diagnosed with obsessive-compulsive disorder\n* willingness to participate in exposure-based treatment\n\nExclusion Criteria:\n\n* intellectual disability\n* autism spectrum disorder that precludes engagement in psychotherapeutic work\n* a psychotic disorder with current psychotic symptoms\n* underweight or very rapid weight loss affecting cognition\n* severe suicidality\n* substance dependence\n* benzodiazepine medication (use of Z-drugs as sleep medication is permitted)\n* In addition, ongoing psychotherapy may prevent participating in the B4DT.",{"count":173,"type":21},65,[70],"The aim of this study is to expand access to Bergen Four-Day Treatment (B4DT) in Finland and to integrate it into psychiatric care pathways at Tampere University Hospital (TAYS). A Bergen team has been established within TAYS Psychiatry and has been trained in collaboration with the B4DT team from HUS and the Norwegian developers. The objective of this study is to enhance understanding of the model's adaptability to the Finnish healthcare system, evaluate healthcare professionals' attitudes toward the intervention, and assess treatment outcomes.\n\nThe aim is to recruit approximately 35 patients for the study. Patients will be recruited from a minimum of three groups (15 patients) and up to a maximum of six groups (35 patients). The criteria for admission to B4DT and for participation in the study are identical. The treatment and the study may include patients receiving specialized psychiatric care at Tampere University Hospital who have been diagnosed with obsessive-compulsive disorder and who experience significant impairment due to their symptoms. In addition, personnel from TAYS Psychiatry who recommend and refer patients for B4DT will be recruited for the study. The estimated number of participating staff members is approximately 30.",[26],[178,179,180,153],"Bergen","B4DT","intensive treatment","2026-06-11",{"date":183,"type":36},"2026-06-12",{"date":185,"type":21},"2026-06",{"date":187,"type":21},"2027-12",{"name":189,"class":87},"Tampere University Hospital",{"id":191,"slug":192,"hasResults":12,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":120,"sex":16,"minAge":64,"maxAge":145,"enrollmentInfo":197,"targetDuration":4,"studyType":68,"phases":199,"briefSummary":200,"conditions":201,"keywords":202,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":203,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":44},"100580201","transcranial-direct-current-stimulation-and-extinction-in-obsessive-compulsive-disorder-100580201","NCT06834217","Transcranial Direct Current Stimulation and Extinction in Obsessive Compulsive Disorder","Characterization and Modulation of Functional Connectivity and Fear Extinction Abnormalities in Obsessive-Compulsive Disorder","Inclusion Criteria:\n\n* All Participant Inclusion Criteria would include:\n\n  1. 18 years of age or older\n  2. speak English fluently, and\n  3. able to provide written and verbal informed consent.\n* Obsessive-compulsive disorder (OCD) Inclusion Criteria would include:\n\n  1. meet criteria for OCD as determined by structured clinical interview\n  2. exhibit significant current symptoms of OCD\n  3. report duration of OCD symptoms of at least 1-year\n  4. OCD symptoms are primary or co-primary relative to other psychiatric diagnoses\n  5. stable psychiatric treatment (≥8-weeks) or no active treatment.\n  6. exhibit significant current symptoms of OCD as determined by the Dimensional Obsessive-Compulsive Scale (DOCS) (≥18).\n\nExclusion Criteria:\n\n* All Participant Exclusion Criteria would include:\n\n  1. active severe substance use disorder(s)\n  2. acute suicidality\n  3. history of bipolar or psychotic disorder(s)\n  4. significant developmental disabilities\n  5. loss of consciousness \\> 10 minutes\n  6. history of traumatic brain injury\n  7. major neurological disease\n  8. a positive pregnancy test\n  9. other brain stimulation or magnetic resonance imaging contraindications\n  10. new psychological treatment within the past 8 weeks\n  11. daily anxiolytic medication use (e.g., benzodiazepine).\n* Non-Clinical Control Exclusion Criteria would include:\n\n  1. meet current criteria for a psychiatric disorder as determined by structured clinical interview\n  2. active-psychotropic medications.",{"count":198,"type":21},180,[70],"Obsessive-compulsive disorder (OCD) is associated with substantial impairments in quality of life and is among the most disabling psychiatric disorders. Exposure therapy is among the first-line of treatments for obsessive-compulsive disorder (OCD) . Extinction learning is thought to be a core mechanism of therapeutic exposure. Fear and safety signal learning are traditionally associated with activity and connectivity within the canonical corticolimbic \"fear circuit\", which includes the amygdala, medial prefrontal cortex (mPFC), and hippocampus. Transcranial direct current stimulation (tDCS) is a neuromodulation technology that can augment brain plasticity, learning, and memory. The proposed study will test if obsessive-compulsive disorder (OCD) is associated with inhibitory safety learning deficits and if transcranial direct current stimulation (tDCS) normalizes functional connectivity and safety signal processing to recover extinction deficits in obsessive-compulsive disorder (OCD).",[26],[75,76,77],{"date":183,"type":36},{"date":205,"type":36},"2025-09-12",{"date":207,"type":21},"2029-08-01",{"name":86,"class":87},{"id":210,"slug":211,"hasResults":12,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":12,"sex":16,"minAge":64,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":68,"phases":218,"briefSummary":219,"conditions":220,"keywords":222,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":238},"100457770","erp-to-improve-functioning-in-veterans-with-ocd-100457770","NCT05240924","ERP to Improve Functioning in Veterans With OCD","Exposure and Response Prevention to Improve Functioning in Veterans With Obsessive Compulsive Disorder","Inclusion Criteria:\n\n* Veterans having a primary diagnosis of Obsessive Compulsive Disorder (OCD)(50% of sample) and comorbid OCD and Post-traumatic stress disorder (PTSD) (50% of sample) who are receiving care from the Michael E. DeBakey VA Medical Center (MEDVAMC) in Houston, TX; the Ralph H. Johnson VA Medical Center in Charleston, SC; the VISN 20 Clinical Resource Hub which provides telehealth services to Washington, Oregon, and Alaska: the VISN 2 Clinical Resource Hub which provides telehealth services to New Jersey, New York, and northern Pennsylvania, and the VISN 6 Clinical Resource Hub which provides telehealth services to North Carolina and Virginia.\n* Willingness to participate in Exposure and Response Prevention(ERP)\n\nExclusion Criteria:\n\n* Significant cognitive impairment or conditions that threaten safety (current psychosis, mania, imminent suicidality including plan or intent, and treatment-interfering moderate to severe substance use).\n* Potential participants taking psychotropic medications must be on a stable dose of these medications for at least 6 weeks prior to study enrollment.",{"count":217,"type":21},160,[70],"Obsessive compulsive disorder (OCD) is a debilitating psychiatric illness impacting work, social, and family functioning. Exposure and Response Prevention (ERP) is the sole evidence-based psychotherapy for OCD; however, no randomized controlled trials (RCTs) have examined the effectiveness of ERP among Veterans or individuals with both OCD and posttraumatic stress disorder (PTSD). This 4-year Hybrid Type I trial will compare outcomes of ERP to those of a control condition among Veterans with OCD. Primary and secondary aims will examine whether Veterans' functioning, quality of life, and OCD symptoms differ between the ERP and control in the full sample of Veterans with OCD, and in the half of the sample with both OCD and PTSD. The tertiary aim is to conduct a mixed-methods formative evaluation of the implementation potential of ERP in VA mental health settings.",[26,221],"Comorbid Post-Traumatic Stress Disorder and OCD",[152,153,223,224,225,226,227],"Post-Traumatic Stress Disorder","PTSD","Worry","Compulsion","Stress","2026-06-04",{"date":230,"type":36},"2026-06-08",{"date":232,"type":36},"2022-10-03",{"date":234,"type":21},"2027-05-31",{"name":236,"class":237},"VA Office of Research and Development","FED",19,{"id":240,"slug":241,"hasResults":12,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":4,"eligibilityCriteria":245,"healthyVolunteers":120,"sex":16,"minAge":64,"maxAge":246,"enrollmentInfo":247,"targetDuration":4,"studyType":68,"phases":249,"briefSummary":250,"conditions":251,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":4},"100625159","feasibility-of-modulating-cognitive-control-in-ocd-100625159","NCT07419009","Feasibility of Modulating Cognitive Control in OCD","Evaluating Frontal Pole as a Window to Modulation of Cognitive Control in OCD","Inclusion Criteria:\n\n* Current primary DSM-5 OCD diagnosis and current Y-BOCS total score of ≥16 (OCD group, only) or no current diagnosis of an emotional disorder, and no known history of OCD, PTSD, anxiety disorder(s), or recurrent major depressive disorder (Healthy participant group, only)\n* 18-60 years of age\n* ability to speak, read, write, and understand English sufficiently well to complete study procedures and provide informed consent\n* psychotherapy and\u002For psychiatric medication use remain stable for 6 weeks prior to study entry\n\nExclusion Criteria:\n\n* Presence of current psychiatric diagnosis (healthy control group, only)\n* active substance use disorder\n* history of mania or hypomania, or lifetime presence of significant psychotic symptoms\n* active suicidal or homicidal ideation\n* use of medications known to reduce seizure threshold (e.g., stimulants)\n* organic brain disease or injury representing a contraindication to TMS\n* any health problems that would interfere with safe and\u002For practical study participation, including contraindications to TMS (e.g., seizure disorder, presence of metal hardware that would come in close contact with the discharging coil)\n* current pregnancy or planning to become pregnant during the study period","60 Years",{"count":248,"type":21},12,[70],"This study tests out procedures to look at whether a type of brain stimulation called transcranial magnetic stimulation impacts flexible shifts in behavior in obsessive-compulsive disorder (OCD). This study examines whether study procedures are feasible and acceptable to people participating in the study, but does not determine whether this type of brain stimulation causes changes.",[73],"2026-05-22",{"date":254,"type":36},"2026-05-27",{"date":256,"type":21},"2026-06-15",{"date":258,"type":21},"2026-10-30",{"name":260,"class":87},"Dartmouth-Hitchcock Medical Center",{"id":262,"slug":263,"hasResults":12,"nctId":264,"briefTitle":265,"officialTitle":265,"acronym":4,"eligibilityCriteria":266,"healthyVolunteers":12,"sex":16,"minAge":64,"maxAge":246,"enrollmentInfo":267,"targetDuration":4,"studyType":68,"phases":269,"briefSummary":270,"conditions":271,"keywords":272,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":44},"100602535","helping-adults-with-obsessive-compulsive-disorder-succeed-at-work-100602535","NCT07124780","Helping Adults With Obsessive-Compulsive Disorder Succeed at Work","Inclusion Criteria:\n\n* Currently unemployed and interested in finding competitive employment in New York State\n* Currently residing in New York State\n* Primary diagnosis of OCD\n* For those currently on psychiatric medication: On a stable dose of psychiatric medication (for at least 6 weeks) and willing to remain on this dose for the first three months of CBT.\n* Access to the internet through a mobile device or computer\n\nExclusion Criteria:\n\n* In the process of applying for or currently receiving disability benefits\n* Currently receiving supported employment services\n* Active suicidality or recent suicide attempt\n* Active substance use problem (other than nicotine) that warrants treatment\n* Comorbid psychiatric conditions that significantly elevate the risk of study participation such as psychotic disorders or bipolar disorder",{"count":268,"type":21},40,[70],"The purpose of this study is to compare two models of employment services for people with obsessive-compulsive disorder (OCD) interested in finding and maintaining employment. All 40 participants will receive up to 12 sessions of the first-line treatment for OCD called exposure and response prevention, a form of Cognitive Behavioral Therapy (CBT). Assigned by chance, half of the people will also receive Individual Placement and Support (IPS); the other half will receive standard vocational services (SVS). This study will compare these two approaches for helping adults with OCD find and maintain work.",[73],[273,274],"supported employment","obsessive-compulsive disorder","2026-05-18",{"date":277,"type":36},"2026-05-19",{"date":279,"type":21},"2026-04-21",{"date":281,"type":21},"2027-08",{"name":283,"class":87},"New York State Psychiatric Institute",{"id":285,"slug":286,"hasResults":12,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":290,"eligibilityCriteria":291,"healthyVolunteers":12,"sex":16,"minAge":64,"maxAge":4,"enrollmentInfo":292,"targetDuration":4,"studyType":68,"phases":294,"briefSummary":295,"conditions":296,"keywords":298,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":44},"100608796","a-lifestyle-intervention-to-reduce-cardiometabolic-risk-factors-in-individuals-with-obsessive-compulsive-disorder-100608796","NCT07206212","A Lifestyle Intervention to Reduce Cardiometabolic Risk Factors in Individuals With Obsessive-compulsive Disorder","Efficacy and Cost-effectiveness of a Lifestyle Intervention to Reduce Cardiometabolic Risk Factors in Individuals With Obsessive-compulsive Disorder: A Randomized Controlled Trial","LIFT","Inclusion criteria:\n\n1. A diagnosis of obsessive-compulsive disorder (OCD), based on the diagnostic criteria of the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders. Screened at registration and at the initial phone call and confirmed by the assessor at the inclusion assessment (psychiatric interview), using a semi-structured diagnostic interview.\n2. Physical inactivity\u002Fsedentarism, operationalized as less than 150 minutes of physical activity per week during the last month, evaluated by asking two questions from the Swedish National Board of Health and Welfare concerning 1) frequency of weekly moderate or vigorous intensity physical exercise and 2) frequency of weekly non-exercise\u002Fdaily life physical activity. Screened at registration and at the initial phone call and confirmed by the assessor at the inclusion assessment (psychiatric interview).\n3. Aged 18 years or older. Screened at registration and confirmed by the assessor at the initial phone call and\u002For confirmed by the assessor at the inclusion assessment (psychiatric interview).\n\nExclusion criteria:\n\n1. Intellectual disability or severe psychiatric symptoms or suicidal risk that could interfere with the intervention. Screened at the initial phone call and confirmed by the assessor at the inclusion assessment (psychiatric interview), using a semi-structured diagnostic interview.\n2. A diagnosis of an eating disorder or a substance use disorder. Screened at the initial phone call and confirmed by the assessor at the inclusion assessment (psychiatric interview), using a semi-structured diagnostic interview.\n3. Being pregnant or \\\u003C1 year postpartum. Screened at the initial phone call and confirmed by the assessor at the inclusion assessment (psychiatric interview).\n4. Myocardial infarction or stroke within the last 6 months. Screened at registration and confirmed by the assessor at the initial phone call and\u002For the inclusion assessment (physiological measures).\n5. Cardiovascular risk measures significantly over the normal range (e.g., severe hypertension \\[blood pressure above ≥180 mmHg systolic or ≥110 mmHg diastolic\\]) or a current somatic condition that make participation in the intervention contraindicated. Screened at registration and confirmed by the assessor at the initial phone call and\u002For the inclusion assessment (physiological measures), after consulting with the study doctor, if necessary.\n6. Initiation or adjustment of any cardiometabolic medication (e.g., blood pressure or blood lipids lowering mediation) within 3 months prior to assessments. Screened at registration and confirmed by the assessor at the initial phone call and\u002For the inclusion assessment (physiological measures).\n7. Inability to understand and communicate in Swedish. Confirmed by the assessor at the initial phone call.\n8. Inability to consistently attend the sessions involved in the intervention. Screened by the assessor at the initial phone call and\u002For confirmed by the assessor at the inclusion assessment (psychiatric interview).\n9. Inability to travel to the sessions involved in the intervention. Screened by the assessor at the initial phone call and\u002For confirmed by the assessor at the inclusion assessment (psychiatric interview).",{"count":293,"type":21},108,[70],"The overall aim of this study is to evaluate the efficacy and cost-effectiveness of a lifestyle intervention to improve lifestyle habits and reduce cardiometabolic risk factors in individuals with obsessive-compulsive disorder (OCD).",[26,297],"Lifestyle (Sedentary Behavior and Physical Activity)",[153,299,300,301,302,303,304],"Obsessive-compulsive disorder","Cardiovascular disease","Metabolic syndrome","Prevention","Lifestyle habits","Physical activity","2026-05-13",{"date":307,"type":36},"2026-05-15",{"date":309,"type":36},"2026-01-30",{"date":311,"type":21},"2028-11-01",{"name":313,"class":87},"Karolinska Institutet",{"id":315,"slug":316,"hasResults":12,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":320,"eligibilityCriteria":321,"healthyVolunteers":12,"sex":16,"minAge":322,"maxAge":64,"enrollmentInfo":323,"targetDuration":4,"studyType":68,"phases":325,"briefSummary":326,"conditions":327,"keywords":341,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":348,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":353,"locationsCount":44},"100587910","implementing-team-based-treatment-for-pediatric-anxiety-in-community-mental-health-settings-100587910","NCT06934525","Implementing Team-Based Treatment for Pediatric Anxiety in Community Mental Health Settings","Testing Delivery of Modalities in Community Health Settings: Developing Pathways to Health Equity","IMPACT-RI","Inclusion Criteria:\n\n* Age 5-18 inclusive\n* Primary or co-primary DSM-V diagnosis of anxiety or OCD\n* Symptom duration of at least 3 months\n* Outpatient care needed\n* Presence of a stable parent, or guardian, who can participate in treatment\n\nExclusion Criteria:\n\n* Other primary or co-primary psychiatric disorder which requires initiation of other active current treatment\n* Acute suicidality\n* Concurrent psychotherapy\n* Chronic medical illness that would preclude their active participation in treatment\n* Treatment with psychotropic medication that is not stable","5 Years",{"count":324,"type":21},501,[70],"The purpose of this study is to test how the delivery of Cognitive Behavioral Therapy (CBT) for pediatric anxiety and OCD via different methods might increase its availability and effectiveness. CBT involves teaching the patient skills to enable them to gradually come into contact with feared situations. This process of gradually approaching feared situations is called exposure. Although CBT with exposure has the best evidence for treating anxiety disorders, not all children have equal access or respond the same way to CBT. As part of this study, patients will receive weekly CBT treatment sessions involving a combination of weekly visits with an exposure coach and one visit a month with a licensed provider (e.g., psychologist, social worker). This treatment will be delivered using one of three methods: 1) in-person (face-to-face sessions, occurring in the office and the home\u002Fcommunity), or 2) telehealth (entirely remote sessions via web-based video conference), or 3) flexible (individualized mix of in-person and\u002For telehealth sessions). Eligible participants will be randomly assigned to one of these three methods. Results of this study will help determine which treatment method works best for whom.\n\nTreatment as described above will occur as part of care at partnering community care sites in Rhode Island. Providers from the following partnering community care sites will make up patient treatment teams: Blackstone Valley Community Health Care, Family Services of Rhode Island, Gateway Healthcare, Newport Mental Health, and Thrive Behavioral Health.\n\nThe research study is being conducted by the Pediatric Anxiety Research Center at Brown University Health. The research team will conduct the study assessments that patients will be asked to participate in as study participants. Patients will be asked to complete assessments prior to starting treatment, at two time points during treatment, at the end of treatment, and at two timepoints 3 and 6 months following the end of treatment. Participants will be compensated for their time completing research assessments.",[26,328,329,330,153,331,332,333,334,335,336,337,338,339,340],"Pediatric Anxiety Disorders","Anxiety Disorder","Anxiety","Phobia","Agoraphobia","Generalized Anxiety","Generalized Anxiety Disorder","Selective Mutism","Separation Anxiety","Social Anxiety","Social Anxiety Disorder","Panic Disorder","Pediatric Disorders",[342,343,344,345,346,347],"exposure therapy","cognitive behavioral therapy","anxiety treatment","exposure and response prevention therapy","ERP","pediatric anxiety treatment",{"date":349,"type":36},"2026-05-14",{"date":351,"type":36},"2025-11-01",{"date":207,"type":21},{"name":354,"class":87},"Bradley Hospital",{"id":356,"slug":357,"hasResults":12,"nctId":358,"briefTitle":359,"officialTitle":359,"acronym":4,"eligibilityCriteria":360,"healthyVolunteers":12,"sex":16,"minAge":64,"maxAge":361,"enrollmentInfo":362,"targetDuration":4,"studyType":68,"phases":364,"briefSummary":365,"conditions":366,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":44},"100637522","explore-neural-mechanism-of-ocd-by-intervention-of-repetitive-transcranial-magnetic-stimulation-with-symptom-provocation-100637522","NCT07587112","Explore Neural Mechanism of OCD by Intervention of Repetitive Transcranial Magnetic Stimulation With Symptom Provocation","Inclusion Criteria:\n\n* Adults aged 18-65 years.\n* Diagnosis of obsessive-compulsive disorder according to DSM-5 criteria. Treatment resistance (i.e., inadequate response to pharmacological or non-pharmacological treatments) is not required.\n* Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score ≥ 14, indicating at least mild to moderate symptom severity.\n\nExclusion Criteria:\n\n* Diagnosis of schizophrenia, organic psychotic disorder, bipolar disorder, alcohol use disorder, or substance use disorder.\n* High suicide risk within the past year.\n* Presence of significant medical or surgical conditions in an active phase.\n* History of, or planned, neurosurgical procedures, or presence of metallic implants in the brain or body (e.g., neurostimulators or cardiac pacemakers).\n* Structural brain abnormalities (e.g., brain tumor or arteriovenous malformation) or neurological disorders (e.g., meningitis, encephalitis, stroke, or epilepsy).\n* Pregnant women.\n* Inability to tolerate PET\u002FMRI examination due to claustrophobia or severe anxiety in confined spaces.\n* Any other conditions that may impair study compliance, including inability to cooperate, failure to provide informed consent, or other investigator-determined ineligibility after screening.\n* Use of medications that may increase seizure risk or suicide risk (e.g., certain antidepressants or antipsychotics).\n* Known allergy to 18F-FDG.\n* History of adverse reaction to TMS or allergy to the positioning cap.\n* Presence of metallic objects within approximately 30 cm of the cranial region (within the stimulation coil area).\n* Prior or current treatment with electroconvulsive therapy (ECT) or vagus nerve stimulation (VNS).","65 Years",{"count":363,"type":21},96,[70],"The purpose of this study is to investigate the differences in therapeutic efficacy of different deep TMS treatment coils and different brain stimulation targets on obsessive-compulsive symptoms, and to explore the neural mechanisms of obsessive-compulsive disorder using functional neuroimaging analysis.\n\n1. Inclusion Criteria:\n\n   Adults aged 18-65 years. Patients diagnosed with obsessive-compulsive disorder according to DSM-5 criteria.\n2. Study Design: Double-blind, randomized assignment.\n3. Number of Participants:\n\n   Sham group: 32 participants Active H7 group: 32 participants Active H1 group: 32 participants Total: 96 participants\n4. Study Procedures:\n\n   \\- Participant Screening and Baseline Assessment (Week 0) Determine eligibility for enrollment, including diagnostic confirmation, symptom assessment, screening for contraindications, and whether the participant has previously experienced adverse effects following TMS treatment. Participants with high suicide risk within the past year will be excluded.\n\n   Develop a personalized symptom provocation procedure for obsessive-compulsive symptoms (Carmi et al., 2018).\n\n   Complete baseline symptom severity assessments and brain positron emission tomography\u002Fmagnetic resonance imaging (PET\u002FMRI). Participants with structural brain abnormalities will be excluded.\n\n   Participants will be randomly assigned (1:1:1) into three groups, with a planned total enrollment of 96 participants.\n\n   Participants currently taking medication may continue their existing regimen, but no medication changes will be allowed during the study period.\n\n   \\- Treatment Phase (Week 1 to Week 6; duration: 6 weeks) Before each TMS session, participants will remove their shoes and socks, rest both hands flat on their thighs, keep their eyes looking straight ahead, and undergo measurement of resting motor threshold (RMT).\n\n   Approximately 3-5 minutes before each TMS session, trained personnel with ERP experience will assist participants in symptom provocation and record the participant's subjective level of distress.\n\n   The deep TMS treatment schedule consists of five sessions per week, one session per day, for six consecutive weeks. Adverse effects will be assessed and monitored at each session.\n\n   After completing the first treatment session, participants will be asked to guess which group they were assigned to, in order to evaluate the effect of treatment expectations on outcomes.\n\n   Symptom severity interviews will be conducted every two weeks.\n\n   \\- Post-treatment Assessment and Follow-up (Week 7 and after; duration: 2 weeks, then 6 months later) Within one week after completion of the deep TMS treatment course (within Week 7), participants will undergo follow-up brain PET\u002FMRI.\n\n   At the end of Week 8 (two weeks after treatment completion), symptom severity will be reassessed. Subsequent treatment plans will be discussed with participants, and outpatient follow-up will be arranged within six months.\n\n   Subsequent treatment options may include cognitive behavioral therapy, pharmacotherapy, and figure-8 rTMS.\n5. Statistical Analysis\n\n   * Expected Outcomes:\n\nThe H7 coil may improve obsessive-compulsive symptoms. Both the H7 and H1 coils may improve mood symptoms.\n\n\\- Descriptive and Inferential Statistics: Analysis of covariance (ANCOVA) will be used to compare differences among the three groups in MADRS, Y-BOCS, HAM-A, HDRS, and CGI-S scores.\n\nThe percentage of responders (% responders) will be calculated and compared among groups.\n\nRepeated-measures ANOVA will be used to examine within-group and between-group differences in symptom improvement before and after deep TMS treatment.\n\nPearson correlation analysis will be used to assess the association between symptom improvement and changes observed in PET\u002FMRI neuroimaging measures.\n\n\\- PET\u002FMRI Neuroimaging Analysis: Functional MRI analyses will include ROI-to-ROI functional connectivity and seed-based functional connectivity analyses.\n\nChanges in PET glucose uptake within specific regions of interest (ROIs) will also be examined to evaluate alterations in neural networks and brain function before and after deep TMS treatment.",[73],"2026-05-08",{"date":349,"type":36},{"date":370,"type":36},"2025-09-22",{"date":372,"type":21},"2027-12-31",{"name":374,"class":375},"Taipei Veterans General Hospital, Taiwan","OTHER_GOV",{"id":377,"slug":378,"hasResults":12,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":4,"eligibilityCriteria":382,"healthyVolunteers":120,"sex":16,"minAge":64,"maxAge":361,"enrollmentInfo":383,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":385,"conditions":386,"keywords":394,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":407,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":413,"locationsCount":165},"100564051","computer-game-qualitative-and-megeeg-assessment-of-serotonergic-psychedelics-100564051","NCT06624137","Computer Game, Qualitative, and MEG\u002FEEG Assessment of Serotonergic Psychedelics","Computationally, Electrophysiologically, and Qualitatively Characterizing Serotonergic Psychedelics; Transdiagnostic Therapeutic and Pro-Psychotic Effects","Inclusion Criteria:\n\n* Participation in approved clinical protocol at Yale University involving potential administration of serotonergic psychedelics\n* Absence of pre-existing psychotic symptoms\n\nExclusion Criteria:\n\n* Current intoxication based on self-report\n* Any neurological, medical or developmental problem that is known to impair cognition significantly based on self-report\n* History of seizures based on self-report\n* Contraindications for MR scanning including metallic implants of any kind, pacemakers and history of accidents with metal, claustrophobia (specific to those who will participate in MRI)",{"count":384,"type":21},200,"This is an observational study which does NOT directly administer a psychedelic substance but rather recruits participants who are already participating in another clinical trial in which they may receive a serotonergic psychedelic. The goal of this observational study is to learn how the brain's information processing changes during and following administration of serotonergic psychedelics (psilocybin, N,N-Dimethyltryptamine\u002FDMT, Lystergic Acid Diethylamide\u002FLSD, etc.) for people with and without mental illness receiving serotonergic psychedelics through any clinical trial at Yale University. The main questions it aims to answer are:\n\n1. Do serotonergic psychedelics cause the brain to rely on new information more than previously learned information while under the influence? What about 1 day, 5-14 days, and 4-6 weeks after use?\n2. Do serotonergic psychedelics cause long-lasting side-effects in how people perceive (see, hear, feel, etc.) the world and how easily people change their beliefs?\n3. How does the brain's electrical activity change after using serotonergic psychedelics? How does the balance between excitation and inhibition change while under their effect?\n4. Can changes in how the brain uses information predict who will benefit from a psychedelic and who will have side effects from psychedelics?\n\nResearchers will compare with people given placebos to see what changes in brain processing are unique to serotonergic psychedelics.\n\nParticipants will have the opportunity to do some combination of the following:\n\n1. Online computer assessments consisting of games and questionnaires that probe how participants think.\n2. Magnetoencephalography (MEG) or electroencephalography (EEG) with eyes closed and with repeated clicks, images, or sensations delivered.\n3. A magnetic resonance imaging (MRI) scan.\n4. Semi-structured qualitative interviews about their experience after taking a serotonergic psychedelic recorded via Zoom.",[153,387,388,27,389,224,390,391,392,26,393],"Major Depressive Disorder (MDD)","Alcohol Use Disorder (AUD)","Migraine","PTSD - Post Traumatic Stress Disorder","Addiction","Tobacco Use Disorder","Opioid Use Disorder",[395,396,397,398,399,400,401,402,403,404,405],"Psilocybin","DMT","N,N-dimethyltryptamine","Ayahuasca","Lysergic acid diethylamide","LSD","5-MeO-DMT","O-methyl-bufotenin","eeg","meg","5-Methoxy-N,N-Dimethyltryptamine","2026-04-27",{"date":408,"type":36},"2026-05-01",{"date":410,"type":36},"2024-12-12",{"date":412,"type":21},"2028-05",{"name":86,"class":87},{"id":415,"slug":416,"hasResults":12,"nctId":417,"briefTitle":418,"officialTitle":419,"acronym":4,"eligibilityCriteria":420,"healthyVolunteers":12,"sex":16,"minAge":64,"maxAge":246,"enrollmentInfo":421,"targetDuration":4,"studyType":68,"phases":422,"briefSummary":423,"conditions":424,"keywords":425,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":433,"locationsCount":44},"100635858","ocd-lifu-target-engagement-100635858","NCT07558148","OCD LIFU Target Engagement","Pilot Study to Investigate Brain Targets for Neuromodulation in Obsessive-compulsive Disorder","Inclusion Criteria:\n\n1\\. Participants must be enrolled in the IRB #853085 study\n\nThe inclusion criteria for the IRB #853085 study, which are also included in this trial are:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Adults aged 18-60 years old\n2. Chronic OCD (5 years preceding date of enrollment), diagnosed as per the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition guidelines (DSM-5)\n3. Presence of obsessions, compulsions, or both time-consuming obsessions and compulsions that take more than one hour a day or cause significant distress or impairment in social, occupation, or other important areas of functioning Obsessive-compulsive symptoms that are not attributable to the physiological effects of a substance (e.g., a drug of abuse, a medication) or another medical condition\n4. Disturbance not better explained by the symptoms of another mental disorder listed in the DSM-5 Severe OCD symptoms, as defined by Y-BOCS I score of 28 or higher, within two weeks prior to enrollment\n5. Compulsions need to involve movement of the hands and\u002For arms so that the sleeve is able to detect participant's actions (cannot be solely mental or verbal compulsions)\n6. Ability to understand procedure-related instructions and to complete study assessments in English, and ability to comply with protocol requirements (e.g., procedure visits, treatment schedule, follow-up visit schedule, evaluations, etc.), in the opinion of the Principal Investigator\n7. Willingness and ability to provide written agreement to allow any and all forms of communication between the research team and treating clinician(s) 8 Willingness and ability to provide informed consent, in the opinion of the Principal Investigator\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Unable to undergo MRI scan\n\n   * Presence of metallic implants or devices or tattoos\n   * Claustrophobia or severe anxiety\n   * Inability to remain still for duration of scan\n2. Inability to fit and wear the ATTN201 device for the entire\n\nExclusion criteria for IRB study #853085 include:\n\n1. Hearing loss that, in the opinion of the Principal Investigator, an audiologist, or a treating physician, is likely to affect the subject's ability to comply with all of the requirements of the study, or may affect the integrity of the study data\n2. Pregnancy - this is an exclusion criterion because we will be intentionally increasing anxiety in participants to evaluate optimal strategies to provoke distress and then promote relaxation\n3. Any past or present medical condition, disease, disorder, or injury that, in the opinion of the Principal Investigator, may reduce or hinder the subject's ability to fully comply with all study requirements for the duration of the study or may impact, compromise, or affect the integrity of the data or results of the study.\n4. Have a previous injury or surgery which could affect the nerve distribution\n5. Have nerve damage (neuropathy)\n6. Have a diagnosed neuromuscular disorder\n7. Have a pacemaker\n8. Have a history of skin allergies, psoriasis eczema, dermatitis, or other skin inflammation conditions\n9. Compulsions cannot be completely mental or verbal actions, such as repeating words, counting objects, or performing mental rituals, and cannot involve only facial muscles\u002Factions such as blinking or staring",{"count":147,"type":21},[70],"The investigators will conduct a pilot study to evaluate the safety and feasibility of low-intensity focused ultrasound on obsessive-compulsive disorder (OCD) symptoms when delivered to subcortical brain targets. The investigators will use the ATTN201 device to deliver single sessions of unfocused and focused ultrasound to up to three brain targets over 4 study visits and assess the intervention through self-rated scales of OCD symptoms.",[26],[153,426],"LIFU","2026-04-22",{"date":429,"type":36},"2026-04-30",{"date":431,"type":36},"2026-03-04",{"date":277,"type":21},{"name":434,"class":87},"University of Pennsylvania",{"id":436,"slug":437,"hasResults":12,"nctId":438,"briefTitle":439,"officialTitle":440,"acronym":441,"eligibilityCriteria":442,"healthyVolunteers":12,"sex":16,"minAge":443,"maxAge":64,"enrollmentInfo":444,"targetDuration":4,"studyType":68,"phases":446,"briefSummary":447,"conditions":448,"keywords":449,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":454,"startDateStruct":456,"completionDateStruct":457,"leadSponsor":459,"locationsCount":44},"100628723","ocd-summer-treatment-program-for-adolescents-in-iceland-100628723","NCT07465354","OCD Summer Treatment Program for Adolescents in Iceland","Intensive OCD Summer Treatment Program for 12-18-year-old Adolescents in Iceland","OCDtreatment","Inclusion Criteria:\n\n* OCD diagnosis\n* Adolescents are fluent in Icelandic\n* Parents are fluent in Icelandic or English\n\nExclusion Criteria:\n\n* Intellectual disability\n* Severe suicidal ideation\n* Acute psychiatric disorders requiring immediate intervention, e.g. schizophrenia\n* Severely impairing levels of autism prohibiting group participation","12 Years",{"count":445,"type":21},70,[70],"The aim of the study is to examine the effectiveness of OCD treatment delivered in a group format for adolescents during a two week intensive summer treatment program.",[73],[299,450,451,452],"Adolescents","intensive cognitive-behavioral treatment","Exposure and response prevention","2026-03-17",{"date":455,"type":36},"2026-03-18",{"date":408,"type":21},{"date":458,"type":21},"2033-09-01",{"name":460,"class":87},"University of Iceland",{"id":462,"slug":463,"hasResults":12,"nctId":464,"briefTitle":465,"officialTitle":466,"acronym":4,"eligibilityCriteria":467,"healthyVolunteers":12,"sex":16,"minAge":64,"maxAge":4,"enrollmentInfo":468,"targetDuration":4,"studyType":68,"phases":469,"briefSummary":470,"conditions":471,"keywords":472,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":476,"startDateStruct":478,"completionDateStruct":480,"leadSponsor":481,"locationsCount":44},"100565854","acceptance-and-commitment-therapy-for-religious-ocd-100565854","NCT06647589","Acceptance and Commitment Therapy for Religious OCD","Efficacy of Acceptance and Commitment Therapy on Religiously Oriented Obsessive-Compulsive Disorder","Inclusion Criteria:\n\n* 18 years old\n* Meet cutoff scores for scrupulosity\n\nExclusion Criteria:\n\n* Presence of psychotic symptoms within six months of screening\n* Current suicidal\u002Fhomicidal plan\u002Fintent and\u002For a suicide\u002Fhomicide attempt within 6 months of screening\n* Non-suicidal self-injury within 6 months of screening\n* Narcotics use within 3 months of screening\n* Purging\u002Frestricting behavior within 3 months of screening.",{"count":147,"type":21},[70],"The purpose of the study is to examine the effects and feasibility of a specific form of psychotherapy, acceptance and commitment therapy (ACT), on religiously oriented obsessive and compulsive disorder (OCD).",[73],[473,474,475,274,153],"scrupulosity","religion","acceptance and commitment therapy",{"date":477,"type":36},"2026-03-19",{"date":479,"type":36},"2025-07-30",{"date":84,"type":21},{"name":482,"class":87},"University of Alabama at Birmingham",{"id":484,"slug":485,"hasResults":12,"nctId":486,"briefTitle":487,"officialTitle":488,"acronym":4,"eligibilityCriteria":489,"healthyVolunteers":12,"sex":16,"minAge":490,"maxAge":4,"enrollmentInfo":491,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":493,"conditions":494,"keywords":514,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":521,"lastUpdatePostDateStruct":522,"startDateStruct":524,"completionDateStruct":526,"leadSponsor":528,"locationsCount":44},"100577917","lhc-cidi-5-in-hong-kong-100577917","NCT06804525","LHC-CIDI-5 in Hong Kong","Use of Life History Calendars to Enhance Measurement of Lifetime Experience With Mental Disorders in Hong Kong.","Inclusion Criteria:\n\n* All household members aged 25 years old and over are randomly sampled from the Census and Statistics Department List of Quarters\n* Live in the address sampled from the Census and Statistics Department List of Quarters\n* Reside in Hong Kong for at least six months in the past year\n* Able to read and communicate in Chinese or English\n* Without linguistic or cognitive difficulties\n\nExclusion Criteria:\n\n* Domestic workers","25 Years",{"count":492,"type":21},2500,"The World Health Organization Composite International Diagnostic Interview-5th (CIDI-5) is a standardized diagnostic tool used to assess the prevalence of mental and substance use disorders over varying time frames (30 days, 12 months, and lifetime) based on the diagnostic criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) and International Classification of Diseases 10th edition (ICD-10). However, retrospective measurements like the CIDI-5 are susceptible to recall bias, especially for the lifetime experience, which can hinder the reporting accuracy with mental disorders.\n\nTo mitigate this issue, the life history calendar (LHC) was introduced as an aid to assist respondents in recalling the timing of life events, enhancing the ability of the CIDI-5 to measure the lifetime prevalence of mental disorders. The LHC is a grid structure with columns representing time units and rows representing life domains under study.\n\nIn a study conducted in Nepal, combining the CIDI-5 with the LHC resulted in a significant increase in the detection of mental disorders compared to using the CIDI-5 alone. This approach did not lead to an increase in false positives after clinical validation.\n\nThis experiment aims to adapt a Hong Kong version of the LHC based on the Nepalese model and evaluate the effectiveness of the LHC-assisted CIDI-5 (LHC-CIDI-5) compared to the CIDI-5 alone in assessing mental disorders.",[495,387,496,497,498,499,500,501,502,503,504,505,506,507,508,509,339,73,510,511,512,388,513],"Major Depressive Episode (MDE)","Persistent Depressive Disorder (PDD)","Suicidal Ideation","Suicidal Plan","Suicidal Attempt","Suicidal Gesture","Nonsuicidal Self-Injury","Manic Episode","Hypomanic","Bipolar I Disorder","Bipolar Sub Disorder","Bipolar II Disorder","Generalized Anxiety Disorder (GAD)","Intermittent Explosive Disorder (IED)","Panic Attack","Posttraumatic Stress Disorder (PTSD)","PCL-SC PTSD","PCL-5 PTSD","Substance Use Disorder (SUD)",[515,516,517,518,519,520],"Life History Calendar","CIDI","Recall bias","Retrospective reporting","Lifetime prevalence","Mental disorders","2026-03-09",{"date":523,"type":36},"2026-03-10",{"date":525,"type":36},"2025-01-18",{"date":527,"type":21},"2027-04",{"name":529,"class":87},"The University of Hong Kong",{"id":531,"slug":532,"hasResults":12,"nctId":533,"briefTitle":534,"officialTitle":535,"acronym":4,"eligibilityCriteria":536,"healthyVolunteers":12,"sex":16,"minAge":64,"maxAge":537,"enrollmentInfo":538,"targetDuration":4,"studyType":68,"phases":540,"briefSummary":541,"conditions":542,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":543,"lastUpdatePostDateStruct":544,"startDateStruct":545,"completionDateStruct":547,"leadSponsor":549,"locationsCount":44},"100601681","the-efficacy-of-temporal-interference-stimulation-in-the-treatment-of-obsessive-compulsive-disorder-100601681","NCT07113652","The Efficacy of Temporal Interference Stimulation in the Treatment of Obsessive-Compulsive Disorder","Exploring the Efficacy of Temporal Interference Stimulation in the Treatment of Obsessive-Compulsive Disorder","Inclusion Criteria:\n\n* 18-50 years old\n* Diagnosis of OCD per DSM-5\n* Y-BOCS score ≥20\n* Have a documented history of at least two adequate trials of selective serotonin reuptake inhibitors (SSRIs). If currently receiving SSRI treatment, the dosage must be stable for at least 8 weeks prior to enrollment\n* With at least 9 years of education\n\nExclusion Criteria:\n\n* Any DSM-5 diagnosis other than OCD (except OCPD)\n* OCD symptoms too severe to complete assessments\n* Received electroconvulsive therapy (ECT) within the past 6 months\n* Received other forms of neuromodulation within the past 2 months（see Item 3 for ECT）\n* Severe medical illness or seizure risk (e.g., cardiovascular, respiratory conditions)\n* Neurological disorders or history of brain injury\u002Fsurgery\n* MRI-incompatible implants (e.g., pacemaker, stents, cochlear implants).\n* Current suicidal risk per investigator judgment\n* Pregnant or planning pregnancy during the study\n* Started structured OCD psychotherapy within 3 months, with expected change during treatment","50 Years",{"count":539,"type":21},18,[70],"This study aims to evaluate the efficacy of Temporal Interference (TI) stimulation in treating patients with obsessive-compulsive disorder (OCD) and to explore its potential neural mechanisms using magnetic resonance imaging (MRI) and electroencephalography (EEG).",[73],"2026-03-07",{"date":523,"type":36},{"date":546,"type":36},"2025-08-17",{"date":548,"type":21},"2027-06",{"name":550,"class":87},"Shanghai Mental Health Center",{"id":552,"slug":553,"hasResults":12,"nctId":554,"briefTitle":555,"officialTitle":556,"acronym":557,"eligibilityCriteria":558,"healthyVolunteers":12,"sex":16,"minAge":559,"maxAge":18,"enrollmentInfo":560,"targetDuration":4,"studyType":68,"phases":562,"briefSummary":563,"conditions":564,"keywords":569,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":575,"startDateStruct":577,"completionDateStruct":579,"leadSponsor":581,"locationsCount":44},"100610481","stepped-care-treatment-for-anxiety-resilience-100610481","NCT07228143","Stepped Care Treatment for Anxiety Resilience","Stepped Care Cognitive Behavioral Therapy for Children and Adolescents With Anxiety","STAR","Inclusion Criteria:\n\n* A primary diagnosis of OCD or an anxiety disorder including separation anxiety disorder, social phobia, generalized anxiety disorder, specific phobia, agoraphobia, panic disorder, as determine by an IE using the DIAMOND-KID diagnostic interview.\n* Score of ≥ 14 on the PARS (items 2-7) which corresponds to clinically significant anxiety.\n* The child is 7-17 years old.\n* Residence in Texas and located in the state of Texas during treatment sessions.\n\nExclusion Criteria:\n\n* -Psychosis, cognitive disability, any condition that would limit the caregiver's ability to follow instructions.\n* Parent substance use disorder within the past 3 months, which could impact their ability to implement step 1\n* Child or parent is suicidal. A delayed entry once the parent or child is stabilized (\\>6 months post suicidality) and no longer has suicidal ideation will be allowed if appropriate.\n* New pharmacological interventions or treatment changes: Initiation of an antidepressant within 12 weeks before study enrollment or 6 weeks for an antipsychotic, benzodiazepine, or attention deficit hyperactivity disorder (ADHD) medication before enrollment, or any change in established psychotropic medication (e.g., antidepressants, anxiolytics) within 6 weeks before study enrollment (4 weeks for antipsychotic, anti-anxiety, benzodiazepine, or ADHD medication changes). Medications will remain stable during treatment.","7 Years",{"count":561,"type":21},106,[70],"Childhood anxiety disorders (CAD) are common and impairing. Family based cognitive behavioral therapy (CBT) is efficacious in treating CAD. Yet, many children do not receive care due to barriers such as limited provider availably, high treatment costs, and constrained family resources (e.g., time). To combat these barriers, other treatment methods have been developed.\n\nThe stepped care treatment models maximize resources by providing low-intensity, low-cost interventions as a first time treatment, while stepping up care for those needing more intensive treatment. Specifically, a stepped care model for CAD that begins with a parent-focus intervention has great promise to deliver efficacious and cost-effective treatment without having to engage the child.\n\nWhile stepped care approaches show promise in treating CAD with comparable efficacy to standard CBT, there remains a large research-to-practice gap. The stepped care model for CAD that begins with a parent-focused intervention has yet been explored, and very little is known about intervention mediators that explain mechanisms of change.\n\nThis research is being done to improve the reach and quality of services using a stepped care model, offering an affordable and practical solution to the widespread gap in youth mental health care.",[507,565,566,567,26,568],"Social Anxiety Disorder (SAD)","Separation Anxiety Disorder","Specific Phobia","Panic Disorder (With or Without Agoraphobia)",[330,570,450,571,572,573],"Child","Obsessive compulsive disorder","stepped care","psychotherapy","2026-02-27",{"date":576,"type":36},"2026-03-02",{"date":578,"type":36},"2026-01-05",{"date":580,"type":21},"2028-04-30",{"name":582,"class":87},"Andrew Wiese",{"id":584,"slug":585,"hasResults":12,"nctId":586,"briefTitle":587,"officialTitle":588,"acronym":4,"eligibilityCriteria":589,"healthyVolunteers":120,"sex":16,"minAge":64,"maxAge":537,"enrollmentInfo":590,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":592,"conditions":593,"keywords":598,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":601,"lastUpdatePostDateStruct":602,"startDateStruct":604,"completionDateStruct":606,"leadSponsor":607,"locationsCount":4},"100623347","assessments-of-obsessive-compulsive-symptoms-in-patients-with-substances-use-disorder-100623347","NCT07395453","Assessments of Obsessive-compulsive Symptoms in Patients With Substances Use Disorder","Assessments of Obsessive-compulsive Symptoms in Patients With Substances Use Disorder and Its Correlates","Inclusion Criteria:\n\n--Adults aged 18-50 years.\n\n* Willing and able to provide informed consent and participate in the study assessments.\n* For the case group: patients with a diagnosed substance use disorder (single or polysubstance) attending the inpatient or outpatient addiction management unit at the Neuropsychiatry Department, Assiut University Hospital.\n* For the control group: relatives, friends, or hospital workers without substance use disorder, recruited through invitation or advertisement.\n\nExclusion Criteria:\n\n* Severe psychiatric comorbidities such as schizophrenia, major depressive disorder, bipolar disorder, or anorexia nervosa.\n* Current intoxication or acute withdrawal state from substances.\n* Severe medical conditions including end-stage renal disease, metastatic cancer, severe heart failure, or chronic obstructive pulmonary disease.\n* Severe cognitive impairment",{"count":591,"type":21},102,"This observational, cross-sectional case-control study evaluates obsessive-compulsive symptoms among adults with substance use disorder compared with a demographically similar control group without substance use disorder. Patients aged 18-50 years attending the addiction management inpatient and outpatient services at Assiut University Hospital, and healthy controls recruited from relatives, friends, and hospital staff, will complete structured clinical interviews, the Yale-Brown Obsessive-Compulsive Scale, and other standardized scales for psychiatric symptoms, cognition, and quality of life. The main objective is to estimate the prevalence and severity of obsessive-compulsive symptoms in substance use disorder and examine their associations with sociodemographic and clinical factors, addiction severity, and quality of life in the recovery stage.",[594,26,595,596,597],"Obsessive - Compulsive Disorder","Obsessive Compulsive Behavior","Substance Abuse Disorder","Substance Use",[599,600],"obsessive-compulsive symptoms","substances use disorder","2026-02-01",{"date":603,"type":36},"2026-02-09",{"date":605,"type":21},"2026-03",{"date":527,"type":21},{"name":608,"class":87},"Assiut University",{"id":610,"slug":611,"hasResults":12,"nctId":612,"briefTitle":613,"officialTitle":614,"acronym":4,"eligibilityCriteria":615,"healthyVolunteers":120,"sex":16,"minAge":616,"maxAge":4,"enrollmentInfo":617,"targetDuration":17,"studyType":22,"phases":4,"briefSummary":619,"conditions":620,"keywords":663,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":686,"lastUpdatePostDateStruct":687,"startDateStruct":689,"completionDateStruct":691,"leadSponsor":693,"locationsCount":44},"100424417","unhide-project-a-digital-health-platform-to-collect-lifestyle-data-for-brain-inflammation-research-100424417","NCT04806620","Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research","Unhide® Project Also Known as The Unhide® Solve Together Unified Platform","Participants may be either self-diagnosed, or diagnosed by a physician with the following conditions:\n\n* Infection-associated chronic conditions such as Long COVID, chronic Lyme, myalgic encephalomyelitis (ME\u002FCFS), and post-acute neuropsychiatric syndrome (PANS\u002FPANDAS).\n* Neuroimmune, developmental, autonomic, and neurological conditions like migraines, dysautonomia, POTS, multiple sclerosis, and autism spectrum disorder.\n* Autoimmune diseases such as Lupus, Sjogren's Disease, rheumatoid arthritis, myasthenia gravis, ankylosing spondylitis, and related autoimmune conditions.\n\nInflammatory gastrointestinal conditions such as Crohn's Disease, Celiac Disease, and ulcerative colitis.\n\n* Behavioral and mood disorders such as anxiety, depression, bipolar disorder, PTSD, eating disorders, OCD, and other related conditions.\n* \"Healthy\" people (without brain inflammation), including unaffected individuals, unaffected individuals in the same household, and unaffected individuals who are married to relatives and family members.\n* Have consistent internet access and a cell phone, tablet, or PC since this is an online or app-based platform that requires entering data and completing surveys.\n* Currently live in the United States\n* Be able to participate in English (stay tuned for updates about the Spanish language version)\n* Be willing to share symptom and health data through the platform","2 Years",{"count":618,"type":21},10000,"The unhide® Project is a non-interventional, longitudinal research study designed to establish a secure data repository of demographic, health, and lifestyle information from individuals with brain inflammation and related neuroinflammatory conditions. Participants in the United States aged 2 years and older will provide self-reported health data, biometrics, and symptom diaries through the MyDataHelps™ app (branded as unhide® for this study). The goal is to create comprehensive longitudinal profiles to facilitate research into disease subtypes, causes, diagnostics, and potential treatments, as well as to identify potential participants for future optional studies. \"Healthy\" individuals without brain inflammation are also eligible to participate.\n\nThe digital health research platform used in this study was originally developed and designed by Solve M.E and was called SolveTogether. The Brain Inflammation Collaborative (BIC) expanded upon Solve M.E.'s work to include related diagnoses, pediatric participants, enhance symptom tracking, and more. BIC and Solve M.E. combined Solve Together and unhide®, to create The unhide® Solve Together Unified Platform in 2025.",[621,622,623,624,625,626,627,628,629,630,631,632,633,634,635,636,637,638,639,640,641,642,643,644,645,646,647,648,649,26,650,651,652,653,390,654,655,656,657,658,659,660,661,662],"Post-Acute COVID-19 Syndrome","ME\u002FCFS","Rheumatic Arthritis","Juvenile Rheumatoid Arthritis (JRA)","Psoriatic Arthritis (PsA)","Ankylosing Spondylitis (AS)","Autoimmune Encephalitis","Celiac Disease","Celiac Disease in Children","Chronic Lyme Disease","Post-treatment Lyme Disease Syndrome","Crohn's Disease","Dysautonomia","Anorexia Nervosa","Bulimia Nervosa","ARFID","Avoidant \u002F Restrictive Food Intake Disorder","Ehlers Danlos Syndrome","Endometriosis","Fibromyalgia (FM)","Long COVID","Lupus","Migraines","Mast Cell Activation Syndrome","Multiple Sclerosis","Myalgic Encephalomyelitis (ME)","Myasthenia Gravis, Generalized","Myasthenia Gravis in Children","Narcolepsy","PANDAS","Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)","POTS - Postural Orthostatic Tachycardia Syndrome","General Anxiety Disorder, Social Anxiety Disorder","Psoriasis","Traumatic Brain Injury","Tourette's Syndrome","Inflammatory Bowel Disease (IBD)","Autoimmune Diseases","Neurological Diseases or Conditions","Psychiatric Disorder","Sjogren's Syndrome","Ulcerative Colitis and Crohn's Disease",[641,664,665,666,667,668,669,670,671,672,622,673,674,675,676,677,643,678,679,680,681,682,683,684,685],"Myalgic Encephalomyelitis","Chronic Fatigue Syndrome","Longitudinal Natural History Study","Observational","Neuroinflammatory Disease","Brain inflammation","Neuroinflammatory disorders","PANS\u002FPANDAS","Autoimmune encephalitis","Dysautonomia \u002F POTS","Multiple sclerosis","Autoimmune disease","Inflammatory bowel disease (Crohn's, ulcerative colitis)","Celiac disease","Mood disorders (anxiety, depression, bipolar, PTSD, OCD)","Mobile health app","Patient registry","Wearable devices","Fatigue","Post-exertional malaise","Brain Fog","Mental health","2026-01-20",{"date":688,"type":36},"2026-01-22",{"date":690,"type":36},"2023-07-05",{"date":692,"type":21},"2030-12-31",{"name":694,"class":87},"Brain Inflammation Collaborative",{"id":696,"slug":697,"hasResults":12,"nctId":698,"briefTitle":699,"officialTitle":700,"acronym":155,"eligibilityCriteria":701,"healthyVolunteers":12,"sex":16,"minAge":64,"maxAge":4,"enrollmentInfo":702,"targetDuration":4,"studyType":68,"phases":703,"briefSummary":704,"conditions":705,"keywords":706,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":708,"lastUpdatePostDateStruct":709,"startDateStruct":711,"completionDateStruct":713,"leadSponsor":715,"locationsCount":44},"100268374","dbs-for-obsessive-compulsive-disorder-100268374","NCT02773082","DBS for Obsessive-Compulsive Disorder","Reclaim™ Deep Brain Stimulation (DBS) Therapy for Obsessive-Compulsive Disorder (OCD)","Inclusion Criteria:\n\n* Have a diagnosis of OCD with a documented duration of at least 5 years\n* Have OCD rated as severe or extreme illness\n* Have failed to improve following treatment with at least 3 selective serotonin reuptake inhibitors (SSRIs) and clomipramine\n* Do not have hoarding as their primary subclassification\n* Have completed or tried to complete Exposure and Response Prevention Therapy (ERP)\n* Have no serious psychiatric disorder in addition to OCD (e.g. comorbid personality disorder) or current substance abuse issues\n* Meet established criteria for implantation of a deep brain stimulation system\n* Are 18 years old or older\n* Have not had a previous surgery to destroy the region of the brain that will be the target of stimulation\n* Are not pregnant\n* Have no other neurological disorders, including dementia\n* Do not have a bleeding disorder or are not taking blood thinners\n* Are capable of giving informed consent\n\nExclusion Criteria:\n\n* Patients who are unable to properly operate the neurostimulator\n* Patients who will be exposed to diathermy",{"count":67,"type":21},[70],"There are two primary approaches to the treatment of OCD, pharmacotherapy and cognitive behavior therapy (CBT). Lack of therapeutic success with one approach leads to trials of the alternative approach or a combination of the two. A rarely used third therapy approach, appropriate for only the most severely afflicted and treatment resistant patients, is neurosurgical ablation of certain brain regions involved in mood and anxiety. The neurosurgical ablation procedures are irreversible in nature, and involve the destruction of specific volumes of brain tissue through various controlled means.\n\nSurgical procedures include cingulotomy, subcaudate tractotomy, limbic leucotomy which is a combination of the first two procedures and capsulotomy. DBS therapy is an alternative to neurosurgical procedures, specifically anterior capsulotomy, for patients with chronic, severe OCD which has proven resistant to primary pharmacological and\u002For behavior therapy options.\n\nResults from 26 severe, treatment-resistant OCD patients treated with DBS at four collaborating centers, three in the US, and one in Europe are summarized in great detail in pages 12-22 of the provided\u002Fattached \"Reclaim Summary of Safety and Probable Benefit.\"",[73],[707,330],"Treatment-Resistant","2025-10-27",{"date":710,"type":36},"2025-10-29",{"date":712,"type":36},"2024-07-06",{"date":714,"type":21},"2030-01-01",{"name":716,"class":87},"Northwell Health",{"id":718,"slug":719,"hasResults":12,"nctId":720,"briefTitle":721,"officialTitle":722,"acronym":723,"eligibilityCriteria":724,"healthyVolunteers":12,"sex":16,"minAge":64,"maxAge":246,"enrollmentInfo":725,"targetDuration":4,"studyType":68,"phases":727,"briefSummary":728,"conditions":729,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":730,"lastUpdatePostDateStruct":731,"startDateStruct":733,"completionDateStruct":735,"leadSponsor":736,"locationsCount":44},"100608210","accelerated-rtms-therapeutic-approach-for-refractory-obsessive-compulsive-disorder-100608210","NCT07198594","Accelerated rTMS Therapeutic Approach for Refractory Obsessive-Compulsive Disorder","A Study on the Efficacy and Safety of Accelerated Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder and Its Underlying Neurological Mechanisms","OCDTMS-IFC","Inclusion Criteria:\n\n* Volunteer subjects with Obsessive Compulsive Disorders (OCD) according to the Diagnostic and Statistical Manual of Mental Disorders (DSM V) criteria\n* without associated tics (\"Gilles de la Tourette\" Syndrome)\n* Age 18-60 years, right-handed\n* Disease severity: Yale-Brown Obsessive Compulsive Scale score ≥16 for OCD patients\n* Medication stable for at least 4 weeks\n* Resistant patients to standard treatments: partial but insufficient response (reduction of Y-BOCS score \\\u003C 35%) or lack of response to previous well conducted treatment including: optimal tolerated dose and adequate duration (\\> 12 weeks) of at least 2 Serotonin Reuptake Inhibitors (selective serotonin reuptake inhibitors, clomipramine), or 1 Serotonin Reuptake Inhibitors + 1 augmentation strategy (adjunction of an antipsychotic - such as risperidone or olanzapine or aripiprazole - or lithium or buspirone)\n* No systematic rTMS therapy in the past six months;\n* Signature of informed consent form;\n* Normal vision or corrected vision;\n* Capacity to complete protocol-specified tests.\n\nExclusion Criteria:\n\n* Abnormal cognitive status (assessed using MoCA with score \\\u003C24);\n* Other primary diagnosis than OCD (comorbid mild depression is tolerated)\n* Comorbid diagnosis of schizophrenia\u002F psychotic disorder, bipolar disorder, substance abuse or dependance3)\n* Significant self-harm intent or severe suicidal tendencies within the past year;\n* Irreversible visual or auditory impairment preventing completion of scales or related assessments;\n* Presence of metallic implants, such as pacemakers or stents;\n* Any current or potential medical, psychological, social, or geographical factors compromising patient safety or study participation;\n* Poor compliance;\n* Claustrophobia;\n* History of epilepsy or familial epilepsy\n* Pregnant or lactating women (women of childbearing potential must obtain a negative pregnancy test result prior to study commencement and employ medically approved contraceptive measures);\n* Deterioration or failure of vital organ function (cardiac, pulmonary, hepatic, renal, etc.); or unstable vital signs;\n* Conditions unsuitable for this stimulation site, such as increased intracranial pressure, elevated intraocular pressure, or glaucoma\n* History of or concomitant neurological disorders: cerebrovascular disease, central nervous system infections, Creutzfeldt-Jakob disease, Huntington's disease and Parkinson's disease, Lewy body dementia, traumatic brain injury dementia, other physical\u002Fchemical factors (drugs, alcohol, CO, etc.), significant somatic diseases (hepatic encephalopathy, pulmonary encephalopathy, etc.), intracranial space-occupying lesions (subdural haematoma, brain tumours), endocrine system disorders (thyroid disease, parathyroid disease), and dementia caused by vitamin deficiency or any other cause",{"count":726,"type":21},20,[70],"The goal of this clinical trial is to learn if individualized accelerated repetitive transcranial magnetic stimulation (rTMS) targeting the inferior frontal cortex combined with symptom provocation works to treat obsessive-compulsive disorders (OCD) in adults. It will also learn about the safety of rTMS over right IFC. The main questions it aims to answer are:\n\n* Does rTMS using a new individualized IFC target relieve participants' OCD symptoms?\n* What medical problems do participants have when taking rTMS?\n\nParticipants will:\n\n* Take rTMS six times per day for 5 consecutive days\n* Visit the clinic once at baseline, the day and four weeks after treatment for checkups and tests",[26,594],"2025-09-21",{"date":732,"type":36},"2025-09-30",{"date":734,"type":36},"2025-07-03",{"date":372,"type":21},{"name":737,"class":87},"Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University"]